Page last updated: 2024-11-05

3-ethylpyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-Ethylpyridine is a heterocyclic organic compound with the formula CH3CH2C5H4N. It is a colorless liquid with a pungent odor. 3-Ethylpyridine is a common impurity in pyridine and is produced as a byproduct of the synthesis of pyridine. It is also a component of coal tar. The compound is a versatile reagent used in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. 3-Ethylpyridine has been studied for its potential biological activity, including its antifungal, antibacterial, and antitumor properties. It has also been investigated as a potential inhibitor of the enzyme acetylcholinesterase, which is involved in the regulation of nerve impulses. Further studies are ongoing to explore its potential as a therapeutic agent.'

3-ethylpyridine: structure given in Merck [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10823
CHEMBL ID23025
CHEBI ID169025
SCHEMBL ID10607
SCHEMBL ID8516560
SCHEMBL ID8516557
MeSH IDM0118634

Synonyms (47)

Synonym
einecs 208-647-2
lutidine, beta-
unii-a25i3ez88v
fema no. 3394
beta-ethylpyridine
a25i3ez88v ,
AKOS009031547
EN300-20087
CHEBI:169025
536-78-7
3-ethylpyridine
pyridine, 3-ethyl-
inchi=1/c7h9n/c1-2-7-4-3-5-8-6-7/h3-6h,2h2,1h
3-ethylpyridine, >=98%, fg
3-ethylpyridine, 98%
3-ethyl-pyridine
CHEMBL23025
E0169
A7811
BP-11274
FT-0615666
3-ethylpyridine [fhfi]
3-ethylpyridine [mi]
3-ethyl pyridine [fcc]
3-ethyl pyridine
AM81306
SCHEMBL10607
DTXSID6060212
SCHEMBL8516560
SCHEMBL8516557
DS-2812
Q-100608
5-ethylpyridine
3-(c2h5)-pyridine
mfcd00006413
beta-lutidine
3-ethylpyridine, technical grade, 94%
151103-56-9
pyridine, 3-ethyl-, radical ion(1+) (9ci)
fema 3394
pyridine,3-ethyl-
3ethylpyridine
BB 0263315
Q27273525
?-ethylpyridine; ?-lutidine
D87724
Z104476778

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The present findings demonstrate the adverse effects of smoke constituents of mammalian reproduction and the differences in sensitivity to smoke components between male and female gametes."( In vitro assessment of reproductive toxicity of cigarette smoke and deleterious consequences of maternal exposure to its constituents.
Liu, M; Wu, SC, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" Pyridines, which were the most abundant class of compounds identified, were purchased, assayed for purity, and tested in dose-response studies on hamster oviducts."( Pyridines in cigarette smoke inhibit hamster oviductal functioning in picomolar doses.
Arey, J; Iv, M; Riveles, K; Talbot, P,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID30377Maximum percent of enhancement of binding.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30378Maximum percent of inhibition of binding was determined1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30389Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 21985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30382Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-10-10e-61985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30391Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 3.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30521Compounds was evaluate for their ability to enhance (+/-)-[3H]nicotine binding at a dose range 10 E -10 - 10 E -6 M was reported1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (20.00)18.7374
1990's0 (0.00)18.2507
2000's4 (40.00)29.6817
2010's4 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.88 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index29.12 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]